bioMérieux S.A. (BIM.PA)

100,00 -2,30 (-2,25%) Alla chiusura: 05:38PM CEST

bioMérieux S.A.

376 Chemin De l’Orme
Marcy-l'Étoile 69280
France
33 4 78 87 20 00
https://www.biomerieux.com

Settore/i: Healthcare
Settore: Diagnostics & Research
Impiegati a tempo pieno: 13.409

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Mr. Pierre Boulud	Chief Executive Officer	1,35M	N/D	1971
Mr. Guillaume Bouhours	Executive VP of Purchasing and Information Systems & CFO	N/D	N/D	1976
Sylvain Morgeau	Investor Relations	N/D	N/D	N/D
Ms. Audrey Dauvet	Executive Vice President of Legal, Corporate Integrity & Public Affairs	N/D	N/D	1974
Ms. Valerie Leylde	Executive Vice President of Human Resources, Communications & CSR	N/D	N/D	N/D
Mr. Pierre Charbonnier	Executive Vice President of Global Quality, Manufacturing & Supply Chain	N/D	N/D	N/D
Mr. Yasha Mitrotti	Executive Vice President of Industrial Applications	N/D	N/D	N/D
Mr. Frederic Beseme	Head of CSR	21,99k	N/D	1956
Jennifer Zinn	Executive Vice President of Clinical Operations	N/D	N/D	N/D
Charles K. Cooper	Executive VP & Chief Medical Officer	N/D	N/D	N/D

Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in EUR.

Descrizione

bioMérieux S.A. develops and produces in vitro diagnostic solutions for the diagnosis of infectious diseases in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers systems that use biological samples, such as blood, saliva, urine, etc. for the diagnosis of infectious diseases, including bacterial infections, parasitic infections, and viral infections; and microbiological control of production or the production environment primarily for food, pharmaceutical, and cosmetic industries. It also provides a suite of software products and services that collect, analyze, and merge various sources of data to make decisions under the BIOMÉRIEUX VISION SUITE name; designs, manufactures, and maintains instruments and software; and designs and manufactures reagents for in vitro diagnostic tests. The company serves clinical and hospital laboratories, physicians, blood banks, vets, and industrial control laboratories. bioMérieux S.A. was formerly known as B-D Mérieux. The company was founded in 1963 and is headquartered in Marcy-l'Étoile, France. bioMérieux S.A. is a subsidiary of Institut Mérieux SA.

Governance aziendale

L'ISS Governance QualityScore di bioMérieux S.A. al 29 aprile 2024 è 9. I criteri di valutazione fondamentali sono revisione: 5; Consiglio di Amministrazione: 8; diritti degli azionisti: 8; retribuzione: 10.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.